ATE241617T1 - Pyrimidinverbindungen - Google Patents

Pyrimidinverbindungen

Info

Publication number
ATE241617T1
ATE241617T1 AT00906531T AT00906531T ATE241617T1 AT E241617 T1 ATE241617 T1 AT E241617T1 AT 00906531 T AT00906531 T AT 00906531T AT 00906531 T AT00906531 T AT 00906531T AT E241617 T1 ATE241617 T1 AT E241617T1
Authority
AT
Austria
Prior art keywords
substituent
formula
optionally substituted
pyrimidine compounds
heteroatom
Prior art date
Application number
AT00906531T
Other languages
English (en)
Inventor
Gloria Anne Breault
Stewart Russell James
Jane Elizabeth Pease
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE241617T1 publication Critical patent/ATE241617T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00906531T 1999-03-06 2000-03-02 Pyrimidinverbindungen ATE241617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905075.9A GB9905075D0 (en) 1999-03-06 1999-03-06 Chemical compounds
PCT/GB2000/000737 WO2000053595A1 (en) 1999-03-06 2000-03-02 Pyrimidine compounds

Publications (1)

Publication Number Publication Date
ATE241617T1 true ATE241617T1 (de) 2003-06-15

Family

ID=10849022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906531T ATE241617T1 (de) 1999-03-06 2000-03-02 Pyrimidinverbindungen

Country Status (20)

Country Link
US (1) US6716831B1 (de)
EP (1) EP1161428B1 (de)
JP (1) JP2002539120A (de)
KR (1) KR100683512B1 (de)
CN (1) CN1227249C (de)
AT (1) ATE241617T1 (de)
AU (1) AU754967B2 (de)
BR (1) BR0008770A (de)
CA (1) CA2366668A1 (de)
DE (1) DE60003001T2 (de)
DK (1) DK1161428T3 (de)
ES (1) ES2200824T3 (de)
GB (1) GB9905075D0 (de)
IL (2) IL145192A0 (de)
MX (1) MXPA01008960A (de)
NO (1) NO320909B1 (de)
NZ (1) NZ513893A (de)
PT (1) PT1161428E (de)
WO (1) WO2000053595A1 (de)
ZA (1) ZA200107252B (de)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
DE60006541D1 (de) * 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
IL149103A0 (en) * 1999-11-30 2002-11-10 Pfizer Prod Inc 2,4-diaminopyrimidine compounds useful as immunosuppressants
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
HUP0400639A3 (en) * 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
ATE430742T1 (de) 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
DE10212098A1 (de) * 2002-03-11 2003-10-23 Schering Ag CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
MEP13408A (en) * 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
MXPA04005181A (es) * 2001-11-30 2005-06-17 Synta Pharmaceuticals Corp Compuestos de pirimidina.
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US20090099160A1 (en) * 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
RS52711B (sr) 2005-05-10 2013-08-30 Incyte Corporation Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
BRPI0610184A2 (pt) 2005-05-16 2012-09-25 Astrazeneca Ab composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
CA2617170A1 (en) * 2005-07-30 2007-02-08 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
JP5119154B2 (ja) 2005-09-22 2013-01-16 インサイト・コーポレイション Ｊａｎｕｓキナーゼの四環系阻害剤
BRPI0616722A2 (pt) * 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
CN101563336A (zh) * 2006-03-16 2009-10-21 诺瓦提斯公司 用于治疗特别是黑素瘤的杂环有机化合物
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
CA2654670A1 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
EP2121692B1 (de) 2006-12-22 2013-04-10 Incyte Corporation Substituierte heterozyklen als inhibitoren von janus-kinase
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP3070090B1 (de) 2007-06-13 2018-12-12 Incyte Holdings Corporation Verwendung der salze des janus-kinasehemmers (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropannitril
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2214486A4 (de) 2007-10-19 2011-03-09 Avila Therapeutics Inc Heteroarylverbindungen und ihre verwendungen
ES2569528T3 (es) 2007-11-16 2016-05-11 Incyte Holdings Corporation 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
PL2288610T3 (pl) 2008-03-11 2017-12-29 Incyte Holdings Corporation Azetydynowe i cyklobutanowe pochodne jako inhibitory jak
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
DK2268635T3 (en) 2008-04-21 2015-09-14 Taigen Biotechnology Co Ltd Heterocyclic Compounds
JP2011518219A (ja) * 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010085246A1 (en) * 2009-01-21 2010-07-29 Praecis Pharmaceuticals Inc 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP3643312A1 (de) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- oder heptannitril als jak-inhibitoren
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EP2448938B9 (de) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinone als pi3k-hemmer
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
CN105541847B (zh) 2009-10-09 2019-08-16 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
CN102844317B (zh) 2010-02-18 2015-06-03 因西特公司 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
EP3050882B1 (de) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl-azetidin-derivate als jak1-inhibitoren
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
EP2675794B1 (de) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selektive fak-inhibitoren
DK2675793T3 (en) 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
ES2547916T3 (es) 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
HK1198579A1 (en) 2011-08-10 2015-04-30 Novartis Pharma Ag Jak p13k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
EP2832734A4 (de) 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclische verbindung
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
AU2013337824B2 (en) 2012-11-01 2018-03-08 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
EA035349B1 (ru) * 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
TWI736135B (zh) 2013-03-01 2021-08-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
SMT202100040T1 (it) 2013-05-17 2021-03-15 Incyte Corp Derivati di bipirazolo come inibitori di jak
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
EP3035966A1 (de) 2013-08-20 2016-06-29 Incyte Corporation Überlebensvorteil bei patienten mit festen tumoren durch erhöhte spiegel des c-reaktiven proteins
CA2940659C (en) 2014-02-28 2023-01-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
KR20240153401A (ko) 2014-04-08 2024-10-22 인사이트 홀딩스 코포레이션 Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료
JP2017514832A (ja) 2014-04-30 2017-06-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ１抑制剤を調製する方法及びその新しい形態
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
EP4086259A1 (de) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclische verbindungen als pi3k-gamma-hemmer
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
EP3399968B8 (de) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
CN108884445A (zh) 2016-03-09 2018-11-23 北京智康博药肿瘤医学研究有限公司 肿瘤细胞悬浮培养物和相关方法
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
IL295978B2 (en) 2017-10-18 2024-01-01 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CN107987054B (zh) * 2017-11-28 2020-05-19 四川大学 一种cdk2抑制剂
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
EP3746429B1 (de) 2018-01-30 2022-03-09 Incyte Corporation Verfahren zur herstellung von (1-(3-fluor-2-trifluormethyl)isonicotinyl)piperidin-4-on)
KR102830476B1 (ko) 2018-02-16 2025-07-08 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
US10947227B2 (en) 2018-05-25 2021-03-16 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MA54947A (fr) 2019-02-15 2021-12-22 Incyte Corp Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020252012A1 (en) 2019-06-10 2020-12-17 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
MX2022001940A (es) 2019-08-14 2022-05-10 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CA3150766A1 (en) 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN119930610A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP7518900B2 (ja) 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4114401A1 (de) 2020-03-06 2023-01-11 Incyte Corporation Kombinationstherapie mit axl/mer- und pd-1/pd-l1-inhibitoren
IL297165A (en) 2020-04-16 2022-12-01 Incyte Corp Soysag tricyclic CRS inhibitors
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
CN115836065B (zh) 2020-06-02 2025-07-01 因赛特公司 制备jak1抑制剂的方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022061351A1 (en) 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
CN112390760B (zh) * 2020-10-15 2022-07-29 北京师范大学 靶向fak的化合物及其制备方法和应用
AU2021396231A1 (en) 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
EP4323405A1 (de) 2021-04-12 2024-02-21 Incyte Corporation Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel
SI4333840T1 (sl) 2021-05-03 2026-01-30 Incyte Corporation Zaviralci poti jak1 za zdravljenje pruriga nodularisa
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CA3224674A1 (en) 2021-07-07 2023-01-12 Pei Gan Tricyclic compounds as inhibitors of kras
EP4370515A1 (de) 2021-07-14 2024-05-22 Incyte Corporation Tricyclische verbindungen als kras-hemmer
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
JP2024542248A (ja) 2021-11-22 2024-11-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
US20230203010A1 (en) 2021-12-03 2023-06-29 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TW202340215A (zh) 2021-12-22 2023-10-16 美商英塞特公司 Ｆｇｆｒ抑制劑之鹽及固體形式以及其製備方法
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
CR20240408A (es) 2022-03-07 2024-11-22 Incyte Corp Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2.
EP4540252A1 (de) 2022-06-14 2025-04-23 Incyte Corporation Feste formen eines jak-hemmers und verfahren zur herstellung davon
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
EP4565229A1 (de) 2022-08-05 2025-06-11 Incyte Corporation Behandlung von nesselsucht mit jak-hemmern
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
EP4698542A1 (de) 2023-04-18 2026-02-25 Incyte Corporation 2-azabicyclo[2.2.1 heptan kras-inhibitoren
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2025096738A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
US20250195536A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
KR20260035991A (ko) 2024-08-26 2026-03-13 인사이트 코포레이션 룩소리티닙의 약학적으로 허용 가능한 염의 국소 피부 제형

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PT664291E (pt) 1992-10-05 2000-11-30 Ube Industries Composto de pirimidina
EP0672035A1 (de) 1993-10-01 1995-09-20 Novartis AG Pyrimidinaminderivate und verfahren zu deren herstellung
DE69434721T2 (de) 1993-10-01 2006-11-09 Novartis Ag Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
DK0672041T3 (da) 1993-10-01 2002-02-25 Novartis Ag Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
CN1102144C (zh) 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
ATE251141T1 (de) 1995-03-10 2003-10-15 Berlex Lab Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
EP0906307B1 (de) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituierte imidazole mit cytokinin-inhibirender wirkung
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
PT988301E (pt) 1997-06-12 2006-10-31 Aventis Pharma Ltd Acetais ciclicos de imidazolilo
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
EP1021173A1 (de) 1997-10-10 2000-07-26 Imperial College Innovations Limited Verwendung von cytokin-unterdrückenden verbindungen (csaid) zur behandlung von gebärmutterkontraktionen
DE69839735D1 (de) 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
NZ506679A (en) 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
SK3842001A3 (en) 1998-09-18 2002-04-04 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors (revised)
JP2002527359A (ja) 1998-09-18 2002-08-27 ビーエーエスエフ アクチェンゲゼルシャフト キナーゼインヒビターとしての４−アミノピロリピリミジン
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
AU6476599A (en) 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
WO2000044750A1 (en) 1999-02-01 2000-08-03 Cv Therapeutics, Inc. PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2002539120A (ja) 2002-11-19
IL145192A (en) 2007-06-17
GB9905075D0 (en) 1999-04-28
NO320909B1 (no) 2006-02-13
DE60003001T2 (de) 2004-05-06
EP1161428A1 (de) 2001-12-12
KR20010102502A (ko) 2001-11-15
NO20014317L (no) 2001-11-01
BR0008770A (pt) 2002-01-08
NO20014317D0 (no) 2001-09-05
CN1227249C (zh) 2005-11-16
ZA200107252B (en) 2002-12-02
KR100683512B1 (ko) 2007-02-16
IL145192A0 (en) 2002-06-30
AU2818700A (en) 2000-09-28
ES2200824T3 (es) 2004-03-16
DE60003001D1 (en) 2003-07-03
EP1161428B1 (de) 2003-05-28
PT1161428E (pt) 2003-10-31
AU754967B2 (en) 2002-11-28
US6716831B1 (en) 2004-04-06
MXPA01008960A (es) 2002-04-24
CA2366668A1 (en) 2000-09-14
WO2000053595A1 (en) 2000-09-14
CN1349528A (zh) 2002-05-15
NZ513893A (en) 2004-03-26
DK1161428T3 (da) 2003-09-15

Similar Documents

Publication Publication Date Title
ATE241617T1 (de) Pyrimidinverbindungen
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
ATE296821T1 (de) Triarylimidazol-derivate als cytokin-inhibitoren
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
ES2185635T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
CA2315050A1 (en) Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
DE60142469D1 (de) Imidinderivate als antineoplastika
DK0418845T3 (da) Pyrazolderivater, fremgangsmåder til fremstilling deraf og farmaceutisk præparat omfattende samme
ATE349432T1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
HUP0100149A2 (hu) Picorna-vírus-ellenes peptidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
HUP0303204A2 (hu) 1-Metilkarbapenem-származékok és ezeket tartalmazó gyógyszerkészítmények
AU8454998A (en) (hetero)aryl-sulfonamide derivatives, their preparation and their use as factor xa inhibitors
AU6731100A (en) Integrase inhibitors containing aromatic heterocycle derivatives
NO20020804L (no) Nye A-500359-derivater
ATE344237T1 (de) Hydroxyacetamidobenzolsulfonamidderivate
AR027035A1 (es) Pirroles sustituidos
PT1351942E (pt) Novos derivados da 2,3-benzodiazepina e composicoes farmaceuticas contendo os mesmos como o ingrediente activo
CA2238723A1 (en) Arylethenesulfonamide derivatives and drug composition containing the same
NO944888L (no) 5-(1,2,4-triazol-1-ylmetyl)-3H-isobenzofuran-1-on derivater, deres fremstilling og anvendelse som aromataseinhibitorer
TH77088A (th) อนุพันธ์พิริมิดีน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1161428

Country of ref document: EP

REN Ceased due to non-payment of the annual fee